The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Open accessAbstract
The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins. Designing molecules that can overcome this protection system and achieve optimal concentration at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery. Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates. This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chemistry strategies toward molecules with optimal brain exposure. A summary of modern CNS pharmacokinetic concepts and methods is also provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Partition coefficients and their uses
Leo, A., Hansch, C., & Elkins, D. (1971) · Chemical Reviews · doi:10.1021/cr60274a001 · Cited by 4,540
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 1,970
Abraham, M. H. (1993) · Chemical Society Reviews · doi:10.1039/cs9932200073 · Cited by 1,968
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Kansy, M., Senner, F., & Gubernator, K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970530e · Cited by 1,304
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Solvent accessible surface area and excluded volume in proteins
Richmond, T. J. (1984) · Journal of Molecular Biology · doi:10.1016/0022-2836(84)90231-6 · Cited by 751
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Modelling of the blood–brain barrier in drug discovery and development
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2368 · Cited by 618
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Intramolecular Hydrogen Bonding in Medicinal Chemistry
Kuhn, B., Mohr, P., & Stahl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100087s · Cited by 571
Young, R. C., Mitchell, R. C., Brown, T. H., Ganellin, C. R., Griffiths, R., Jones, M., Rana, K. K., Saunders, D., & Smith, I. R. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00398a028 · Cited by 521
On The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
Temperature dependence of 1H chemical shifts in proteins
Baxter, N. J., & Williamson, M. P. (1997) · Journal of Biomolecular NMR · doi:10.1023/a:1018334207887 · Cited by 497
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
The P-Glycoprotein Efflux Pump: How Does it Transport Drugs?
Sharom, F. J. (1997) · Journal of Membrane Biology · doi:10.1007/s002329900305 · Cited by 458
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Ritchie, T. J., Macdonald, S. J. F., Young, R. J., & Pickett, S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.014 · Cited by 442
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups
Jamieson, C., Moir, E. M., Rankovic, Z., & Wishart, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060379l · Cited by 423
Self-citationCorrelation of Drug Absorption with Molecular Surface Properties
Palm, K., Luthman, K., Unge, A.-L., Strandlund, G., & Artursson, P. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950285r · Cited by 412
In vitro models for the blood–brain barrier
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R. D., Lindmark, T., Mabondzo, A., Nilsson, J. E., Raub, T. J., et al. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.06.011 · Cited by 394
Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.
Paul, D., Standifer, K. M., Inturrisi, C. E., & Pasternak, G. W. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20832-1 · Cited by 393
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Syvänen, S., Lindhe, Ö., Palner, M., Kornum, B. R., Rahman, O., Långström, B., Knudsen, G. M., & Hammarlund-Udenaes, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024745 · Cited by 359
Estimation of ADME Properties with Substructure Pattern Recognition
Shen, J., Cheng, F., Xu, Y., Li, W., & Tang, Y. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100104j · Cited by 349
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2
del Amo, E. M., Urtti, A., & Yliperttula, M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.015 · Cited by 319
Computational approaches to the prediction of the blood–brain distribution
Norinder, U., & Haeberlein, M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00005-4 · Cited by 305
Demystifying Brain Penetration in Central Nervous System Drug Discovery: Miniperspective
Di, L., Rong, H., & Feng, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301297f · Cited by 304
Uetrecht, J. P. (1999) · Chemical Research in Toxicology · doi:10.1021/tx980249i · Cited by 304
The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier
Kageyama, T., Nakamura, M., Matsuo, A., Yamasaki, Y., Takakura, Y., Hashida, M., Kanai, Y., Naito, M., Tsuruo, T., Minato, N., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02758-x · Cited by 298
SHEN, D., ARTRU, A., & ADKISON, K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.011 · Cited by 286
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Absorption Classification of Oral Drugs Based on Molecular Surface Properties
Bergström, C. A. S., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., & Artursson, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020986i · Cited by 247
Parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics
Hansch, C., Steward, A. R., Anderson, S. M., & Bentley, D. L. (1968) · Journal of Medicinal Chemistry · doi:10.1021/jm00307a001 · Cited by 233
Fridén, M., Winiwarter, S., Jerndal, G., Bengtsson, O., Wan, H., Bredberg, U., Hammarlund-Udenaes, M., & Antonsson, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901036q · Cited by 230
Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier
Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Moghrabi, A., & Béliveau, R. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00201-x · Cited by 220
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds
Hitchcock, S. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201136z · Cited by 217
Maurer, T. S., DeBartolo, D. B., Tess, D. A., & Scott, D. O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001222 · Cited by 214
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Johnson, D. S., Stiff, C., Lazerwith, S. E., Kesten, S. R., Fay, L. K., Morris, M., Beidler, D., Liimatta, M. B., Smith, S. E., Dudley, D. T., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100190t · Cited by 199
Fridén, M., Gupta, A., Antonsson, M., Bredberg, U., & Hammarlund-Udenaes, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015222 · Cited by 199
Kalvass, J. C., Polli, J. W., Bourdet, D. L., Feng, B., Huang, S.-M., Liu, X., Smith, Q. R., Zhang, L. K., & Zamek-Gliszczynski, M. J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.34 · Cited by 197
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Chen, Y., Agarwal, S., Shaik, N. M., Chen, C., Yang, Z., & Elmquist, W. F. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154781 · Cited by 194
Multi-objective optimization methods in drug design
Nicolaou, C. A., & Brown, N. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2013.02.001 · Cited by 192
Drug interactions at the blood-brain barrier: Fact or fantasy?☆
Eyal, S., Hsiao, P., & Unadkat, J. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.017 · Cited by 186
Reichel, A. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900103 · Cited by 185
Rational Use of Plasma Protein and Tissue Binding Data in Drug Design
Liu, X., Wright, M. R., & Hop, C. E. C. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5007935 · Cited by 184
Liu, X., Smith, B. J., Chen, C., Callegari, E., Becker, S. L., Chen, X., Cianfrogna, J., Doran, A. C., Doran, S. D., Gibbs, J. P., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079319 · Cited by 181
Liu, X., Van Natta, K., Yeo, H., Vilenski, O., Weller, P. E., Worboys, P. D., & Monshouwer, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024125 · Cited by 179
H1 Antihistamines: Current Status and Future Directions
Simon, F. E. R., & Simons, K. J. (2008) · World Allergy Organization Journal · doi:10.1186/1939-4551-1-9-145 · Cited by 171
McTigue, M. A., Deng, Y. L., Liu, W., Brooun, A., & Stewart, A. E. (2014) · Worldwide Protein Data Bank · doi:10.2210/pdb4ctb/pdb · Cited by 170
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport
Di, L., Artursson, P., Avdeef, A., Ecker, G. F., Faller, B., Fischer, H., Houston, J. B., Kansy, M., Kerns, E. H., Krämer, S. D., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.015 · Cited by 167
Tang, S. C., Lagas, J. S., Lankheet, N. A. G., Poller, B., Hillebrand, M. J., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26000 · Cited by 165
Impact of Lipophilic Efficiency on Compound Quality
Tarcsay, Á., Nyíri, K., & Keserű, G. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201388p · Cited by 164
Species Independence in Brain Tissue Binding Using Brain Homogenates
Di, L., Umland, J. P., Chang, G., Huang, Y., Lin, Z., Scott, D. O., Troutman, M. D., & Liston, T. E. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038778 · Cited by 160
Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring
Piel, M., Vernaleken, I., & Rösch, F. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5001858 · Cited by 159
Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses
Debruyne, D. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733010-00005 · Cited by 153
A new multidrug resistance protein at the blood–brain barrier
Eisenblaetter, T., & Galla, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00376-5 · Cited by 149
Wan, H., Rehngren, M., Giordanetto, F., Bergström, F., & Tunek, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070375w · Cited by 143
How hydrogen bonds impact P-glycoprotein transport and permeability
Desai, P. V., Raub, T. J., & Blanco, M.-J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.059 · Cited by 141
Rampe, D., Wible, B. A., Brown, A. M., et al. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13362-2 · Cited by 140
Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B. M., Dillard, L. W., & Singh, S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301659n · Cited by 135
Kodaira, H., Kusuhara, H., Fujita, T., Ushiki, J., Fuse, E., & Sugiyama, Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180398 · Cited by 132
Morphy, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512185 · Cited by 123
Utility of CSF in translational neuroscience
de Lange, E. C. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9301-9 · Cited by 121
Wu, D., Kang, Y., Bickel, U., & Pardridge, W. M. (1997) · PubMed · Cited by 119
High Throughput Method for the Indirect Detection of Intramolecular Hydrogen Bonding
Goetz, G. H., Farrell, W. P., Shalaeva, M. Y., Sciabola, S., Anderson, D. P., Yan, J., Philippe, L., & Shapiro, M. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401859b · Cited by 119
Predicting and Improving the Membrane Permeability of Peptidic Small Molecules
Rafi, S. B., Hearn, B. R., Vedantham, P., Jacobson, M. P., & Renslo, A. R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201634q · Cited by 117
Sadiq, M. W., Borgs, A., Okura, T., Shimomura, K., Kato, S., Deguchi, Y., Jansson, B., Björkman, S. E., Terasaki, T., & Hammarlund‐Udenaes, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22567 · Cited by 103
Seelbach, M. J., Brooks, T. A., Egleton, R. D., & Davis, T. P. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04644.x · Cited by 102
Toward an improved prediction of human in vivo brain penetration
Summerfield, S., Lucas, A. J., Porter, R., Jeffrey, P., Gunn, R., Read, K., Stevens, A. J., Metcalf, A., Osuna, M. C., Kilford, P., et al. (2008) · Xenobiotica; the fate of foreign compounds in biological systems · doi:10.1080/00498250802499459 · Cited by 101
Desai, P. V., Sawada, G. A., Watson, I. A., & Raub, T. J. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300555n · Cited by 98
Reversible Michael Additions: Covalent Inhibitors and Prodrugs
Johansson, M. H. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575112091330 · Cited by 96
Over, B., McCarren, P. R., Artursson, P., Foley, M. A., Giordanetto, F., Grönberg, G., Hilgendorf, C., Lee, M. D., Matsson, P., Muncipinto, G., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500059t · Cited by 90
Shalaeva, M. Y., Caron, G., Abramov, Y. A., O’Connell, T. N., Plummer, M. S., Yalamanchi, G., Farley, K. A., Goetz, G. H., Philippe, L., & Shapiro, M. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301850m · Cited by 89
Dounay, A. B., Anderson, M. D., Bechle, B. M., Campbell, B. M., Claffey, M. M., Evdokimov, A. G., Evrard, E., Fonseca, K. R., Gan, X., Ghosh, S., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200204m · Cited by 89
Hsiao, P., Sasongko, L., Link, J. M., Mankoff, D. A., Muzi, M., Collier, A. C., & Unadkat, J. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097931 · Cited by 89
Polli, J. W., Baughman, T. M., Humphreys, J. E., Jordan, K. H., Mote, A. L., Salisbury, J. A., Tippin, T. K., & Serabjit‐Singh, C. J. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10453 · Cited by 89
Stain‐Texier, F., Boschi, G., Sandouk, P., & Scherrmann, J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702873 · Cited by 88
Shuttle‐Mediated Drug Delivery to the Brain
Malakoutikhah, M., Teixidò, M., & Giralt, E. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006565 · Cited by 85
Ashwood, V. A., Field, M. J., Horwell, D. C., Julien-Larose, C., Lewthwaite, R. A., McCleary, S., Pritchard, M. C., Raphy, J., & Singh, L. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010825z · Cited by 82
Strategies to optimize brain penetration in drug discovery.
Liu, X., & Chen, C. (2005) · PubMed · Cited by 80
Challenges for blood–brain barrier (BBB) screening
Jeffrey, P., & Summerfield, S. G. (2007) · Xenobiotica · doi:10.1080/00498250701570285 · Cited by 79
Westerhout, J., Danhof, M., & de Lange, E. C. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22604 · Cited by 76
Chernet, E., Martin, L. J., Li, D., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.04.075 · Cited by 76
Zhao, R., Raub, T. J., Sawada, G. A., Kasper, S. C., Bacon, J. A., Bridges, A. S., & Pollack, G. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025064 · Cited by 74
Giri, N., Shaik, N., Pan, G., Terasaki, T., Mukai, C., Kitagaki, S., Miyakoshi, N., & Elmquist, W. F. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020974 · Cited by 70
Ball, K., Bouzom, F., Scherrmann, J., Walther, B., & Declèves, X. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9496-0 · Cited by 67
Weiss, M. M., Williamson, T. L., Babu‐Khan, S., Bartberger, M. D., Brown, J., Chen, K., Cheng, Y., Citron, M., Croghan, M. D., Dineen, T. A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300119p · Cited by 66
Ball, K., Bouzom, F., Scherrmann, J., Walther, B., & Declèves, X. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23266 · Cited by 66
Steady-State Brain Concentrations of Antihistamines in Rats
Doan, K. M. M., Wring, S. A., Shampine, L. J., Jordan, K. H., Bishop, J. P., Kratz, J., Yang, E., Serabjit‐Singh, C. J., Adkison, K. K., & Polli, J. W. (2004) · Pharmacology · doi:10.1159/000079137 · Cited by 65
Prediction of blood–brain barrier penetration: are we missing the point?
Martin, I. J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02961-1 · Cited by 64
Alelyunas, Y. W., Empfield, J. R., McCarthy, D. J., Spreen, R. C., Bui, K., Pelosi-Kilby, L., & Shen, C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.068 · Cited by 61
Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
Lerchner, A. M., Machauer, R., Betschart, C., Veenstra, S. J., Rueeger, H., McCarthy, C., Tintelnot‐Blomley, M., Jaton, A.-L., Rabe, S., Desrayaud, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.092 · Cited by 58
Kuduk, S. D., Marco, C. N. D., Chang, R. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061094b · Cited by 56
New quinoline NK3 receptor antagonists with CNS activity
Smith, P. W., Wyman, P. A., Lovell, P. J., Goodacre, C. J., Serafinowska, H. T., Vong, A. K. K., Harrington, F. P., Flynn, S. T., Bradley, D. M., Porter, R. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.005 · Cited by 56
Frölich, N., Dees, C., Paetz, C., Ren, X., Lohse, M. J., Nikolaev, V. O., & Zenk, M. H. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.001 · Cited by 51
Ward, S. E., Harries, M. H., Aldegheri, L., Andreotti, D., Ballantine, S. P., Bax, B. D., Harris, A. J., Harker, A. J., Lund, J., Melarange, R. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1005429 · Cited by 47
Högberg, T., Frimurer, T. M., & Sasmal, P. K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.025 · Cited by 45
Cutler, L., Howes, C., Deeks, N. J., Buck, T., & Jeffrey, P. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20658 · Cited by 45
Hu, E., Kunz, R. K., Chen, N., Rumfelt, S., Siegmund, A., Andrews, K. L., Chmait, S., Zhao, S., Davis, C. D., Chen, H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401234w · Cited by 44
Wang, X., Ratnaraj, N., & Patsalos, P. N. (2004) · Seizure · doi:10.1016/j.seizure.2004.01.007 · Cited by 42
Targeted Covalent Enzyme Inhibitors
Noe, M. C., & Gilbert, A. M. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00027-8 · Cited by 41
Zhao, R., Kalvass, J. C., Yanni, S. B., Bridges, A. S., & Pollack, G. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019893 · Cited by 40
Raub, T. J., Lutzke, B. S., Andrus, P. K., Sawada, G. A., & Staton, B. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-44961-6_16 · Cited by 35
Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists
McCoull, W., Barton, P., Brown, A., Bowker, S. S., Cameron, J., Clarke, D. S., Davies, R. D. M., Dossetter, A. G., Ertan, A., Fenwick, M. L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500610n · Cited by 34
Gianotti, M., Botta, M., Brough, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100856p · Cited by 28
Goldberg, F. W., Dossetter, A. G., Scott, J. S., Robb, G. R., Boyd, S., Groombridge, S. D., Kemmitt, P. D., Sjögren, T., Gutierrez, P. M., deSchoolmeester, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4016729 · Cited by 26
Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists
McDonald, I. M., Mate, R. A., Zusi, F. C., Huang, H. B., Post-Munson, D. J., Ferrante, M. A., Gallagher, L., Bertekap, R. L., Knox, R. J., Robertson, B., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.070 · Cited by 25
Tardia, P., Stefanachi, A., Niso, M., Stolfa, D. A., Mangiatordi, G. F., Alberga, D., Nicolotti, O., Lattanzi, G., Carotti, A., Leonetti, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500697c · Cited by 25
Something's got to give: psychiatric disease on the rise and novel drug development on the decline
Chandler, D. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.003 · Cited by 24
A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Moghaddam, M. F., Tang, Y., O’Brien, Z., Richardson, S., Bacolod, M. D., Chaturedi, P., Apuy, J. L., & Kulkarni, A. A. (2014) · Drug Metabolism Letters · doi:10.2174/1872312808666140317151735 · Cited by 18
Designing CNS Drugs for Optimal Brain Exposure
Ranković, Z. (2015) · doi:10.1002/9781118788523.ch18 · Cited by 11
Medicinal Chemistry Challenges in CNS Drug Discovery
Bingham, M. J., & Ranković, Z. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00465 · Cited by 11
Feasibility of combining EGFR- and VEGF(R)-targeted agents in colorectal cancer.
Larsen, A. K., Poindessous, V., Ouaret, D., Ouadrani, K. E., Mégalophonos, V. F., Batistella, A., Petitprez, A., Escargueil, A. E., Tournigand, C., & de Gramont, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.443 · Cited by 7
Cited by
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Daina, A., & Zoete, V. (2016) · ChemMedChem · doi:10.1002/cmdc.201600182 · Cited by 2,549
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
Metadata
- Authors
- Rankovic, Z.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-01-06
- Volume
- 58
- Issue
- 6
- Pages
- 2584-2608
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2321980425
- Cited by
- 548
- References
- 152
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.